Algorae Pharmaceuticals Partners with Cadila for Cardiovascular & Metabolic Drug Commercialization in Australia & New Zealand
Algorae Pharmaceuticals (ASX: 1AI) is expanding its commercial reach in Australia and New Zealand through a new partnership with Indian pharmaceutical giant Cadila Pharmaceuticals, focused on bringing two generic medicines for cardiovascular and metabolic disorders to market. The collaboration signifies a strategic move for Algorae to leverage Cadila’s manufacturing capabilities while bolstering its own regulatory and marketing expertise within the region.
Expanding Commercial Platform with Cadila Partnership
Under a definitive license and supply agreement, Cadila Pharmaceuticals will assume responsibility for the product development and manufacture of the generic medications. Algorae’s subsidiary, AlgoraeRx, will manage the crucial aspects of Therapeutic Goods Administration (TGA) sponsorship, regulatory submissions, and marketing activities throughout Australia and New Zealand.
Cadila Pharmaceuticals is a leading, privately-held pharmaceutical company in India, boasting fully integrated operations encompassing active pharmaceutical ingredients, finished formulations, contract research, and manufacturing services. The company currently distributes its products in over 100 countries across Asia, Africa, Europe, and the Americas. Its robust research and development division employs over 350 scientists dedicated to key therapeutic areas including respiratory, cardiometabolic, gastrointestinal, oncology, anti-infective, and pain management.
Complementing Existing Licensing Agreements
This partnership with Cadila builds upon Algorae’s existing commercial framework. The company already has a licensing agreement with Sakar Healthcare for the launch of five generic oncology medicines in Australia and New Zealand. Furthermore, Algorae maintains a distribution agreement with Dr Reddy’s Laboratories to supply the chemotherapy medicine Capecitabine 500mg to the Australian market.
“Collectively, these deals establish a multi-partner, multi-therapy commercial platform spanning oncology, cardiovascular, and metabolic diseases targeting hospitals, pharmacies, and other institutional customers,” according to a company release. Algorae anticipates commencing TGA registration planning and documentation for the Cadila cardiovascular and metabolic medicines, with updates to shareholders regarding submission timelines, anticipated launch windows, and projected revenue contributions as the program progresses.
AlgoraeOS Validation at Peter MacCallum Cancer Centre
Algorae’s commercial endeavors are closely aligned with its ongoing research and development initiatives in the oncology sector, conducted at the prestigious Peter MacCallum Cancer Centre in Melbourne. The centre has played a pivotal role in the independent pre-clinical validation of the AlgoraeOS drug-combination prediction platform, both Version 1 and the recently launched Version 2 upgrade.
The upgraded Version 2 incorporates confidence-weighted predictions and full dose-response modelling across multiple synergy metrics. Validation efforts generated approximately 10,000 data points across 84 cannabidiol-drug-cell line combinations, confirming the platform’s ability to effectively prioritize combinations demonstrating genuine biological synergy. Independent validation of Version 2 is intended to further mitigate risk and refine the pipeline, focusing on combinations with the highest translational potential.
This strategic combination of commercial partnerships and innovative research positions Algorae Pharmaceuticals for continued growth within the Australian and New Zealand pharmaceutical markets.
